Phase 2 Alopecia Areata Trial, Recruiting NCT07533006 Sponsor: Eli Lilly and Company Condition: Alopecia Areata
Back to Alopecia Areata

Phase 2 Alopecia Areata Trial, Recruiting

NCT07533006
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with severe Alopecia Areata (a condition causing significant hair loss on the scalp)
  • Your hair loss covers between 50% and 90% of your scalp, as measured by a standard hair loss scoring tool
  • Your current episode of severe hair loss has been going on for at least 6 months but no longer than 4 years
  • In your doctor's opinion, your hair has not significantly grown back on its own in at least the past 6 months
  • You are willing to avoid using any hair loss treatments during the study

Who may not be able to join:

  • Your hair loss is mainly the "diffuse" type, which means hair is shedding thinly and widely across the scalp rather than in patches
  • You are currently experiencing another type of hair loss condition
  • You have an unstable ongoing health condition that requires frequent hospital stays or regular use of medications that suppress the immune system (confirm with trial site)
  • You have previously taken JAK inhibitor medications by mouth (a specific type of drug used to treat certain immune conditions)
  • You have had a major surgery in the past 8 weeks, or you expect to need major surgery during the study
  • You have a history of, or currently have, serious or unstable conditions affecting the heart, lungs, liver, digestive system, hormones, blood, brain, or mental health

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company

Phone: 1-317-615-4559

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
14 April 2026
Est. completion
1 June 2027

Where this trial is recruiting

🇨🇦 Canada 🇨🇳 China 🇳🇱 Netherlands 🇵🇱 Poland 🇰🇷 South Korea 🇬🇧 United Kingdom 🇺🇸 United States

Primary endpoints

Percentage of Participants Achieving an Absolute Severity of Alopecia Tool (SALT) Less than or Equal to (≤) 20

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov